Objective: To analyze the histopathological indicators significantly associated with surgical outcome and the pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy (CRT) and subsequent pancreatectomy. Background: Clinicopathological assessment of the resected specimen is an indispensable tool for predicting patient prognosis and localizing high-risk sites for tumor relapse. This procedure is also essential for the establishment of efficient postoperative follow-up protocols in the setting of a preoperative CRT strategy. Methods: In a prospective phase II clinical trial at our hospital, 110 patients received preoperative CRT and subsequent resection. All 110 resected cases were included in this study. We employed disease-free survival (DFS) as a surgical outcome, and the pattern of recurrence was divided into 2 categories: (1) recurrence in the abdominal cavity (RAC), defined as either a locoregional or a peritoneal recurrence; or (2) distant recurrence (DR), defined as cancer recurrence in a distant organ. Clinicopathological variables were analyzed in association with DFS, RAC, and DR. Results: Positive nodal involvement and perineural invasion were independent factors that were significantly associated with an unfavorable DFS (P = 0.021 and P = 0.026, respectively). The presence of perineural invasion was the single independent variable significantly associated with an increased risk of RAC (P = 0.002), whereas the status of nodal involvement was the single independent variable significantly associated with an increased risk of DR (P = 0.013).
localized disease is the only treatment option that potentially provides a cure. However, the 5-year survival rate of patients with resectable PC is reported to be as low as 10% to 25% because of the high risk of local and/or distant recurrence, even after a margin-negative resection (R0 resection) is obtained. [2] [3] [4] [5] Because surgical resection alone seems to afford the minimum survival benefit, a variety of multimodal approaches for the treatment of PC have been applied. [5] [6] [7] [8] [9] [10] Preoperative chemoradiation therapy (CRT) with subsequent surgery is one of the promising treatment strategies for PC. 8, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Several characteristics of preoperative CRT have presumably contributed to favorable outcomes in the setting of preoperative CRT with subsequent surgery. First, the preoperative CRT strategy discriminates between patients who are likely to benefit from subsequent surgery and those who are not. 8, 15, 16, [22] [23] [24] [25] More specifically, patients with occult distant disease and with exceptionally aggressive tumors demonstrate unresectable factors during the preoperative treatment period, and thus, these patients can avoid a subsequent resection that is unlikely to be beneficial. Second, the macroscopic and microscopic levels of down staging provided by the locoregional effects of preoperative CRT could lower the rates of margin-positive resections compared with those obtained without preoperative CRT. 5, 8, 13, 15 Although patients who received resections for PC after preoperative CRT have a lower incidence of locoregional recurrence and a more favorable 5-year survival rate, ranging from 36% to 53% in previous reports, a substantial number of patients still develop tumor recurrence in a variety of sites. 8, [10] [11] [12] [13] [14] [15] 26 Therefore, a clinicopathological assessment of the resected specimen is an indispensable tool for predicting patient prognosis and localizing high-risk sites for tumor relapse. This procedure is also essential for the establishment of an efficient postoperative follow-up protocol. Furthermore, such predictive information is useful for considering both the use of postoperative adjuvant therapy and the selection of an optimal second-line chemotherapeutic agent for improved outcome.
Various histopathological variables have been found to predict prognosis after surgical resection in the up-front surgery strategy. [27] [28] [29] [30] [31] [32] [33] [34] However, the association between surgical outcome, pattern of recurrence, and histopathological variables has not been fully investigated in the setting of preoperative CRT strategy. 8, [10] [11] [12] [13] [14] [15] 26 The histopathological prognostic factors determined after a resection following preoperative CRT might be different from those in the up-front surgery strategy because of the characteristic treatment effects provided by preoperative CRT. The patient-selection effects of preoperative CRT, followed by subsequent resection, create a more enrichedchemoradiation-resistant malignancy. [17] [18] [19] The histopathological features in resected specimens after preoperative CRT are usually altered considerably, such that each histopathological variable might have a different clinical significance than in the setting of an upfront surgery strategy. Moreover, several authors have attempted to evaluate the histopathological alterations of the primary tumor as an indicator of the efficacy of the preoperative treatment (ie, histopathological response to preoperative treatment), and thus the prognostic significance of this response is also of interest. 18, 19, 35, 36 Therefore, this study was conducted to evaluate the histopathological variables and to determine the indicators significantly associated with surgical outcome and with a pattern of recurrence in the setting of preoperative gemcitabine-based CRT and subsequent pancreatectomy.
PATIENTS AND METHODS

Patients
A total of 131 treatment-naïve patients with T3-PC (according to the UICC classification, 7th edition), proven based on either histopathological or cytological examination, enrolled in a prospective phase II clinical trial (UMIN-CTR: UMIN000001804) of preoperative gemcitabine-based CRT and subsequent surgery at our hospital between 2002 and 2009. 37 Although five patients temporarily interrupted radiation therapy because of possible cholangitis from a biliary stent occlusion, all 131 patients ultimately completed the radiation protocol. Among them, 10 (7.6%) patients were ineligible for laparotomy because unresectable factors were revealed at restaging, after completion of the preoperative CRT (Fig. 1 ). In total, 121 patients received laparotomy, and of these, 11 (8.4%) patients were ineligible for resection because of unresectable factors detected during laparotomy (Fig. 1) . Consequently, 110 patients received surgical resection after the completion of preoperative CRT (resection rate: 84%). No R2 resection (resection with macroscopic residual tumor) cases occurred. The final 110 resected cases were included in this FIGURE 1. Algorithm of the clinical processes (n = 131). Ten patients (7.6%) did not undergo laparotomy because of local diseases (n = 1), liver metastases (n = 8), and lung metastases (n = 1) manifested at restaging after the completion of preoperative CRT. Eleven patients (8.4%) did not undergo resection because of local diseases (n = 4), liver metastases (n = 3), and peritoneal metastases (n = 4) detected during laparotomy. Consequently, the remaining 110 patients received resection after the completion of preoperative CRT (resection rate: 84%). study to evaluate the histopathological variables associated with surgical outcome and pattern of recurrence after resection.
Protocol of Preoperative CRT and Subsequent Surgery
The details of our preoperative gemcitabine-based CRT have been described in a previous report. 15 Briefly, 3-dimensional radiation was administered at a total radiation dose of 50 Gy with a daily fraction of 2 Gy 5 times a week. The radiation targeted the following fields: the primary pancreatic tumor, the celiac and superior mesenteric arteries, the retroperitoneal soft tissue, and the para-aortic region. Intravenous administration of gemcitabine (1000 mg/m 2 ) was initiated concurrently on days 1, 8, and 15 during each 4-week cycle; this procedure was performed repeatedly for 3 cycles, such that the preoperative CRT was completed 3 months after initiation (Fig. 2) .
Evaluation of the resectability of the PC was performed before the initiation of preoperative CRT, at the completion of preoperative CRT and at laparotomy (Fig. 2) . The evaluation was based on a radiographic imaging study, including thin-sliced abdominal/thoracic computerized tomography, magnetic resonance imaging or celiac/superior mesenteric arteriography, which was also intraoperatively performed during the laparotomy. The exclusion criteria for resection of the PC were as follows: presence of distant diseases (M1) and cancer invasion into the root of the celiac truncus, the superior mesenteric artery, or the confluent point of the right colic vein to the superior mesenteric vein. When a patient was determined to be unresectable by restaging at the completion of preoperative CRT, further surgical treatment was deemed to be without merit; these patients were instead treated with clinically relevant chemotherapy. In patients whose PC was intraoperatively determined to be unresectable, gastrointestinal and/or choledocointestinal bypass was performed if clinically indicated; these patients were then treated with clinically relevant chemotherapy after surgery. The surgical approach included pancreatectomy accompanied by extensive lymphatic and connective tissue clearance combined with postoperative liver perfusion chemotherapy (LPC; details published previously). 38, 39 When a tumor recurrence was determined, further treatment was not specified, and various chemotherapies and/or radiation therapies were applied based on the clinical indication.
FIGURE 2.
Protocol of preoperative CRT and subsequent surgery. Three-dimensional radiation was administered at a total radiation dose of 50 Gy with a daily fraction of 2 Gy five times a week. Intravenous administration of gemcitabine (1000 mg/m 2 ) was initiated concurrently on days 1, 8, and 15 during each 4-week cycle; this protocol was performed consecutively for 3 cycles, such that the preoperative CRT was completed 3 months after initiation. Evaluation of the resectability of the pancreatic cancer was performed before the initiation of preoperative CRT, at the completion of preoperative CRT, and at laparotomy. 1 LPC indicates liver perfusion chemotherapy.
Histopathological Examination of Resected Specimen
All tumors were evaluated according to the pathological TNM (pTNM) classification and the guideline provided by the College of American Pathologists. 37, 40, 41 The histopathological variables evaluated in this study are listed in Table 1 . Specifically, evaluation of the histopathological response of the primary tumor to the preoperative CRT was performed using a grading schema described by Evans et al (histologic appearance, Table 1) . 35 In brief, the histologic appearance was classified according to the following five grades: Grade I, little (<10%) or no tumor cell destruction is evident; Grade IIa, 10% to 50% of tumor cells are destroyed; Grade IIb, 51% to 90% of tumor cells are destroyed; Grade III, few (<10%) viable-appearing tumor cells are present; Grade IV, no viable tumor cells and sizable pools of mucin are present (complete pathological response). 35 In addition, 
Surveillance Protocol After Surgery
After the surgical resection of the PC, each patient received the following protocol as a standard postoperative follow-up with a focus on surveying the patient for any tumor relapse: (1) monthly routine laboratory tests, including tumor markers, and routine radiographic imaging studies every 3 months during the first-year postsurgery, (2) routine laboratory tests and routine radiographic imaging studies every 3 months during the second year postsurgery, and (3) routine laboratory tests and routine radiographic imaging studies 2 to 3 times per year thereafter. Recurrence of the PC was determined based on the findings of radiographic imaging studies and other clinical manifestations. Additional examinations, such as positron emission tomography/computed tomography and cytological and histopathological examinations, were also available for the determination of recurrence of pancreatic cancer when clinically indicated. Figure 3 shows the overall survival (OS) and disease-free survival (DFS) for the 110 resected cases after preoperative CRT. In this study, we employed DFS as a surgical outcome for the following reasons: (1) to avoid the influence of inhomogeneity in the treatment after cancer relapse, (2) to emphasize the analysis for pattern of recurrence, and (3) to reflect the finding that survival curves of OS and DFS were virtually parallel as shown in Figure 3 . The clinicopathological variables listed in Table 1 were analyzed in association with DFS and the pattern of recurrence.
Clinicopathological Variables Analyzed in This Study and Statistical Analyses
Univariable and multivariable analyses of DFS and specific hazards for a certain pattern of recurrence were performed using a Cox stepwise regression to determine the significant clinicopathological variables. In each of these analyses, P values were calculated using the likelihood test, and only variables with a univariable P ≤ 0.1 were considered for entry into the multivariable Cox model, to avoid the possibility of obtaining spurious results. Stratified Kaplan-Meier curves were created to visually display the effect of each variable on DFS and specific hazards for a certain pattern of recurrence with the log-rank test. P values below 0.05 were considered significant. All analyses were performed using the SPSS statistical software package (version 11.0; SPSS, Inc., Chicago, IL).
FIGURE 3.
Overall and disease-free survival (n = 110). The 5-year overall and disease-free survival rates were 56% and 50%, respectively. Note that the survival curves of OS and DFS were virtually parallel. 
RESULTS
Clinicopathological Characteristics of 110 Patients With Preoperative CRT and Subsequent Resection
The clinicopathological characteristics of the 110 resected cases are summarized in Table 1 . Positive nodal involvement was observed in 19 patients (17%). The majority of patients (n = 102, 93%) had tumors of well or moderate differentiation (G1 or G2 according to UICC classification), and the remaining 8 patients had G3 tumors (poorly differentiated adenocarcinoma).
37 R0 (pathologically margin-negative) resection was achieved in 108 patients (98%). Residual tumor cells with a histologically viable appearance were estimated at less than 10% (ie, classified as grade III or IV according to Evans classification) in 16 patients (15%) and at more than 10% (ie, grade I or II) in the remaining 94 patients. 35 Residual tumor cells with a histologically viable appearance were estimated at less than 5% (ie, classified as grade IIIb or IV) in 8 patients (7%) and at more than 5% (ie, grade I, II, or IIIa) in the remaining 102 patients. Complete pathological responses (grade IV) were observed in 3 patients. Perineural invasion and lymph-vascular invasion in the peripancreatic area were observed in 56 (51%) and 32 (29%) patients, respectively. Each of the clinicopathological variables was dichotomized as shown in Table 1 for further analyses.
Association of Clinicopathological Variables With DFS and a Pattern of Recurrence
At the last follow-up, 45 incidents of tumor recurrence were observed in 34 (30.9%) of the 110 patients who received preoperative CRT and subsequent surgery; details of the recurrences sites are summarized in Table 2 . In this study, the pattern of recurrence was divided into the following 2 groups: (1) recurrence in the abdominal cavity (RAC), defined as either locoregional or peritoneal recurrence, which indicates a recurrence presumably due to occult residual tumor cells left behind at the time of resection; and (2) distant recurrence (DR), defined as cancer recurrence in a distant organ (eg, liver, lung, bone, and other distant organs), which indicated a recurrence presumably due to systemic tumor spread that was undetectable at the time of resection and could not be controlled by the systemic administration of gemcitabine during the preoperative treatment. The univariable associations of the clinicopathological variables with DFS, RAC, and DR are summarized in Table 3 . The status of nodal involvement, vascular invasion, histologic appearance (viable tumor cells ≥10% vs. <10%), lymph-vascular invasion, and perineural invasion was significantly associated with DFS in the univariable analyses. Among those significant variables, the status of nodal involvement and perineural invasion was also significantly associated with both RAC and DR, whereas the status of vascular invasion and lymph-vascular invasion was significantly associated solely with RAC (Table 3 ). In the multi- *Others includes skin (n = 1), adrenal gland (n = 1), and Virchow lymph node (n = 2).
variable Cox stepwise regression model, positive nodal involvement and the presence of perineural invasion were independent factors that were significantly associated with unfavorable DFS (Table 4 ). Figure 4A shows the Kaplan-Meier curve for DFS according to the status of nodal involvement. The 5-year DFS rates in patients who had negative nodal involvement (n = 91) and those who had positive involvement (n = 19) were 58% and 0%, respectively. Figure 4B shows the Kaplan-Meier curve for the DFS according to the status of perineural invasion. In this case, the 5-year DFS rates in patients without perineural invasion (n = 54) and those with perineural invasion (n = 56) were 74% and 26%, respectively. In the multivariable Cox stepwise regression model for RAC, the presence of perineural invasion was the single independent variable significantly associated with an increased risk of RAC (Table 4 ). Figure 4C shows the Kaplan-Meier curve for freedom from RAC according to the status of perineural invasion. A majority of patients without perineural invasion did , with 5-year 1 DFS rates of 58% and 0%, respectively (P < 0.001). B, Kaplan-Meier curve for 1 DFS according to the status of perineural invasion. Patients without perineural invasion (n = 54) had significantly more favorable 1 DFS compared to those with perineural involvement (n = 56), with 5-year 1 DFS rates of 74% and 26%, respectively (P < 0.001). C, Kaplan-Meier curve for freedom from 2 RAC according to the status of perineural invasion. Notably, a majority of patients without perineural invasion did not develop 2 RAC, whereas approximately half of the patients with perineural invasion developed 2 RAC within 3 years after resection. D, Kaplan-Meier curve for freedom from 3 DR according to the status of nodal involvement. Notably, all patients with positive nodal involvement developed 3 DR within 3 years after resection, whereas more than 70% of patients with negative nodal involvement did not develop 3 DR at 5 years after resection. 1 DFS indicates disease-free survival. 2 RAC indicates recurrence in the abdominal cavity, defined as either locoregional or peritoneal recurrence. 3 DR indicates distant recurrence, defined as cancer recurrence in a distant organ. 4 N indicates nodal involvement.
not develop RAC, whereas approximately half of the patients with perineural invasion developed RAC 3 years after resection. In the multivariable Cox stepwise regression model for DR, the status of nodal involvement was the single independent variable significantly associated with an increased risk of DR (Table 4 ). Figure 4D shows the Kaplan-Meier curve for freedom from DR according to the status of nodal involvement. All patients with positive nodal involvement developed DR within 3 years after resection, whereas more than 70% of patients with negative nodal involvement did not develop DR 5 years after resection.
DISCUSSION
Several histopathological prognostic analyses on resected specimens have been performed in the setting of an up-front surgery strategy, but few such analyses have been performed in a preoperative treatment strategy setting. [27] [28] [29] [30] [31] [32] [33] [34] In recent years, an increasing number of reports have described characteristic treatment effects and subsequent favorable outcomes in the setting of preoperative CRT for resectable PC. 8, 10, 11, 13, 15 In this study, we performed detailed histopathological prognostic analyses using well-known histopathological predictors from an up-front surgery strategy; in addition, we evaluated the histopathological response of the primary tumor to preoperative CRT, using a large number of patients in a single institution. 18, 19, 35, 36 Reviewing previous reports on the histopathological prognostic factors of resected PC, the status of pathological margins (R status), nodal involvement, histologic grade, perineural invasion, and lymph-vascular invasion are widely known to be prognostic predictors in an up-front surgery strategy. [27] [28] [29] [30] [31] [32] [33] [34] However, in this study, the statuses of nodal involvement and perineural invasion were both significantly associated with DFS, whereas the 3 other factors failed to reach significance. Presumably, the effects of CRT prior to resection influenced the prognostic significance of each histopathological factor, leading to these differences. Unexpectedly, the histopathological response to preoperative CRT (histologic appearance) also failed to show significance in this study. 35 Indeed, it remains controversial whether or not those histopathological assessments of the degree of tumor destruction caused by preoperative treatment (histopathological response to preoperative CRT) provide an adequate evaluation of the locoregional treatment efficacy of preoperative treatment and an accurate prognosis. More specifically, the histopathological responses successfully showed significant associations with surgical Copyright © 2011 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. outcome in some reports, but these responses failed to show the same results in other studies. 8, 14, [16] [17] [18] [19] [20] Controversy concerning the clinical significance of the histopathological response to preoperative CRT could be caused by issues related to the reproducibility and accuracy of evaluating the histopathological features. Although the histopathological response is generally evaluated by comparing the residual viable with nonviable tumor cells, there is no simple means for identifying those cells. 18, 19, 35, 36 In addition, some noncancerous histopathological findings, such as fibrotic changes due to preexisting pancreatitis and radiation therapy, could mimic those originating from PC, and the discrimination between these features is usually difficult. In contrast to the simple and straightforward determination of the status of nodal involvement and perineural invasion, the uncertainties involved in histopathological determinations reduce the reproducibility and objectivity of the assessment of the histopathological response to preoperative CRT. Another potential explanation for the controversy regarding the clinical significance of the histopathological response to preoperative CRT is that the pathophysiology and treatment efficacy in the locoregional area, which reflects the degree of the histopathological response, might not closely represent those in the systemic host-tumor relationship. In spite of the favorable locoregional control, distant failure is the predominant pattern of recurrence in previous reports regarding preoperative CRT, as found here. 8, 14 Even more surprisingly, 1 of the 3 complete responders in our cohort developed tumor recurrences (lung metastases). White et al also reported a concordant observation, showing that 2 of 4 complete responders in their preoperative CRT study experienced tumor recurrences. 19 These results indicate that patients with a predominant locoregional response (even a complete pathological response) can still harbor distant recurrences, which may be the origin of the controversy concerning the histopathological response to preoperative CRT as a prognostic predictor.
High frequencies of positive nodal involvement and perineural invasion are the key factors that characterize the clinical manifestations of PC. 42 The frequencies of nodal involvement and perineural invasion are typically reported to be more than 70%. 29, 30, 33, 34, [42] [43] [44] [45] [46] The prognostic significance of nodal involvement has been reported in previous papers in the setting of preoperative CRT. 8, 14, 17, 19 Breslin et al reported that the survival of patients with negative nodal involvement was significantly more favorable than those with positive involvement, with the median survival being 25 and 19 months, respectively.
14 White et al reported that the median survival times of patients with negative and positive nodal involvement were 29 and 18 months, respectively. 19 Similarly, in this study, the prognostic significance of nodal involvement was more definitively demonstrated; the 5-year DFS rates of patients with negative and positive nodal involvement were 58% and 0%, respectively (P < 0.001). Although the prognostic significance of perineural invasion in a preoperative CRT strategy has not been previously well documented in the setting of preoperative CRT, this study indicates its potential prognostic significance.
Notably, both of these histopathological features showed clear associations with different patterns of recurrences in this study. Positive nodal involvement was the single independent predictor significantly associated with an increased risk of DR. This observation suggests that positive nodal involvement indicates a high possibility of the systemic spread of tumor cells that survive despite systemic gemcitabine chemotherapy during the preoperative treatment period. Positive nodal involvement could indicate the tendency of the tumor to spread to distant sites through systemic blood or lymphatic pathways and the resistance to systemic gemcitabine administration. Meanwhile, the presence of perineural invasion demonstrated a different clinical significance: it was the one independent predictor significantly associated with an increased risk of RAC. Previous reports have suggested that perineural invasion occurred near the primary lesion and extended to the extrapancreatic nerve plexus through the perineural space in a continuous fashion. 27, 28, 46, 47 Therefore, the presence of perineural invasion in the peripancreatic area after preoperative CRT might indicate a tumor biology that aggressively extends into the locoregional area and shows resistance to gemcitabine-based CRT. In this characteristic tumor biology, occult residual tumor cells are very likely to be present even after an R0 resection, ultimately leading to an increased risk of RAC. In these contexts, it would also be interesting to explore the prognostic significance of the various biogenetic factors known to be associated with tumor progression (eg, SMAD4/DPC4 and EpCAM), gemcitabine resistance (eg, human equilibrative nucleoside transporter-1 and RRM1), and radioresponsiveness (eg, REG 4). [48] [49] [50] [51] [52] [53] [54] [55] Further investigations regarding these factors as potential prognostic factors will contribute to improved prognostic predictions and deeper insights into the biogenetic mechanisms associated with treatment responsiveness in the setting of preoperative CRT strategy.
The impact of the gemcitabine dose is also important when discussing the prognostic factors in gemcitabine-based CRT. Evans et al reported preoperative CRT with a gemcitabine dose of 400 mg/m 2 ; the most common gemcitabine dose used in preoperative CRT is approximately 400 to 600 mg/m 2 . 8, 16, [56] [57] [58] Small et al and Talamonti et al reported full-dose (1000 mg/m 2 ) gemcitabine-based CRT, which we used in this study. 13, 15, 59 Given that previous studies have shown that even a minimally cytotoxic concentration of gemcitabine potently enhances the locoregional tumor radioresponse, the difference in the preoperative CRT with full-dose versus lower dose gemcitabine regimens might be manifested more evidently in their systemic treatment efficacies rather than their locoregional treatment effects. [60] [61] [62] Although even full-dose gemcitabine had modest systemic treatment effects in advanced disease (but significantly superior effects compared to 5-FU), the difference between full-dose and low-dose gemcitabine may be enhanced in a patient population with a potentially low systemic tumor burden, such as those who are eligible for preoperative CRT for resectable PC. 8, 24, 63 Thus, the difference in the gemcitabine dose in the setting of gemcitabine-based preoperative CRT might have an impact on the pattern of recurrence after a subsequent resection, particularly on the risk for a systemic recurrence, which potentially influences the prognostic significance of each clinicopathological factor. A comparative study exploring the differences in the prognostic factors across various preoperative CRT protocols will be very useful to improve our understanding of the pathophysiologies behind the treatment failures in patients treated by preoperative CRT and ultimately contribute to improve the outcomes in the setting of preoperative CRT strategy for PC. Further investigation is required to address these issues.
There are several potential benefits of the results of this study for the practice of preoperative CRT for PC. First, knowledge about the specific sites that are at high risk of recurrence after resection is quite beneficial. More efficient postoperative surveillance can be performed with a focus on the pattern of recurrence, enabling the follow-up protocol to be optimized for each individual patient. For example, because patients with positive perineural invasion are at high risk of RAC, abdominal computed tomography should be central to the postoperative imaging surveillance in these cases. In cases with positive nodal involvement, patients are at high risk of DR, indicating that systemic surveillance by positron emission tomography/computed tomography might be the most efficient diagnostic tool. Second, as mentioned earlier, the status of nodal involvement and perineural invasion can be simply and reproducibly evaluated histopathologically even in prominently deteriorated histology after preoperative CRT in addition to its potent significance for predicting the postoperative course. In this regard, the status of those factors could serve as a supplementary indicator for the histopathological response, thereby facilitating evaluation of the efficacy of the preoperative treatment. Further investigation is needed to determine the optimal indicators of the histopathological response to preoperative treatment. Third, prognostic information based on nodal involvement and perineural invasion will be useful in developing appropriate adjuvant treatment strategies and determining optimal chemotherapeutic treatments if tumor relapse occurs.
There are limitations to this study. Because the effects of preoperative CRT are considered to be multifactorial and various clinical steps are involved in the protocol, the complexity of preoperative CRT potentially leads to unknown biases that influence the outcome. A multiple-institution prospective study would be better able to reduce the likelihood of these unexpected biases and would provide more conclusive results concerning the prognostic significance of histopathological variables in the future.
In conclusion, the status of nodal involvement and perineural invasion in resected specimens are significantly associated with DFS in the setting of a preoperative gemcitabine-based CRT strategy. Furthermore, the status of those factors is clearly associated with a specific pattern of recurrence. Predictive information concerning the pattern of recurrence based on those histopathological variables will contribute to the development of efficient follow-up protocols and reasonable adjuvant treatment strategies, as well as to the determination of optimal treatments for tumor relapses, in the setting of preoperative CRT. Further investigation is required to evaluate whether or not this predictive information, based on histopathological evaluation, ultimately contributes to the improvement of surgical outcomes and to a better understanding of the pathophysiology of PC. 
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